I'm bullish on Harrow due to the VEVYE Access for All program, which makes dry eye treatment affordable and drives strong prescription growth. VEVYE's discounted pricing addresses a massive, ...
Harrow's focused acquisition model in ophthalmic drugs enables high growth, with a diversified portfolio and limited R&D expenses. My DCF analysis suggests a fair value of $72.75 per share—nearly 100% ...
Hosted on MSN
Harrow, Inc. (HROW) Emerges as Eye Care Powerhouse With Biosimilars to Lucentis and Eylea
We recently compiled a list of the 11 Best Pharma Stocks to Invest in for the Long Term. Harrow, Inc. is one of them. Harrow, Inc. (NASDAQ:HROW), a leading U.S.-based pharmaceutical company, is ...
Investors might want to bet on Harrow (HROW), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback